February 6, 2018 10:03 AM EST
News Briefing

Nes­san Berming­ham re­turns to VC life; Sanofi's gener­ics unit gets two in­dus­try bid­ders in EMS and Tor­rent Phar­ma

Amber Tong

→ Now that In­tel­lia Ther­a­peu­tics $INTL is sail­ing steadi­ly to­ward its first hu­man stud­ies with Ab­b­Vie vet John Leonard at the helm, Nes­san Berming­ham will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times